NOVATO, Calif., Jan. 2, 2013 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biotechnology company, today announced that Emil D. Kakkis, M.D., Ph.D, the company's CEO, will be presenting at the 2013 31st Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2013 at 8:30am Pacific Time. The conference is being held at the Westin St. Francis Hotel in San Francisco, CA.
Ultragenyx is a privately held, development-stage biotechnology company committed to bringing to market life-transforming therapeutics for patients with rare and ultra-rare metabolic genetic diseases. The company focuses on diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no effective treatments.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx' strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at www.ultragenyx.com.
CONTACT: Ultragenyx Pharmaceutical Inc. For Media, Bee Nguyen For Investors, Shalini Sharp 415-483-8800Source:Ultragenyx Pharmaceutical Inc.